Importer of Controlled Substances; Notice of Application, 53605-53606 [E7-18497]
Download as PDF
<![CDATA[
53605
rwilkins on PROD1PC63 with NOTICES
Federal Register / Vol. 72, No. 181 / Wednesday, September 19, 2007 / Notices
Industries (202–205–3349 or
eric.land@usitc.gov). For more
information on legal aspects of the
investigation, contact William Gearhart
of the Commission’s Office of the
General Counsel (202–205–3091 or
william.gearhart@usitc.gov). The media
should contact Margaret O’Laughlin,
Office of External Relations (202–205–
1819 or margaret.olaughlin@usitc.gov).
Hearing-impaired individuals may
obtain information on this matter by
contacting the Commission’s TDD
terminal at 202–205–1810. General
information concerning the Commission
may also be obtained by accessing its
Internet server (https://www.usitc.gov).
The public record for this investigation
may be viewed on the Commission’s
electronic docket (EDIS–ONLINE) at
https://www.usitc.gov/secretary/
edis.htm. Persons with mobility
impairments who will need special
assistance in gaining access to the
Commission should contact the Office
of the Secretary at 202–205–2000.
Background: As requested by the
USTR, in accordance with section
503(a)(1)(A), 503(e), and 131(a) of the
Trade Act of 1974, as amended (19
U.S.C. 2463(a)(1)(A), 19 U.S.C. 2151(a)),
and pursuant to section 332(g) of the
Tariff Act of 1930 (19 U.S.C. 1332(g)),
the Commission will provide advice as
to the probable economic effect on U.S.
industries producing like or directly
competitive articles and on consumers
of the elimination of U.S. import duties
for all beneficiary developing countries
under the GSP program on articles
provided for in HTS subheadings
2613.10.00, 2613.90.00, 2917.12.10,
3204.17.90, 4412.39.5030, 7601.10.30,
7601.20.30, 7604.21.00, and
8111.00.4910. Also, as requested by
USTR, pursuant to section 332(g) of the
Tariff Act of 1930, the Commission will
provide advice as to the probable
economic effect on U.S. industries
producing like or directly competitive
articles and on consumers of the
removal from eligibility for duty-free
treatment under the GSP program of
articles provided for in HTS
subheadings 2931.00.90 from India and
3920.62.00 from Brazil. As requested by
the USTR, the Commission will provide
its advice no later than December 19,
2007. The USTR indicated that those
sections of the Commission’s report and
related working papers that contain the
Commission’s advice will be classified
as ‘‘confidential.’’
Public Hearing: A public hearing in
connection with this investigation will
be held beginning at 9:30 a.m. on
October 16, 2007 at the United States
International Trade Commission
Building, 500 E Street SW., Washington,
VerDate Aug<31>2005
17:49 Sep 18, 2007
Jkt 211001
DC. All persons have the right to appear
by counsel or in person, to present
information, and to be heard. Persons
wishing to appear at the public hearing
should file a letter with the Secretary,
United States International Trade
Commission, 500 E St., SW.,
Washington, DC 20436, not later than
the close of business (5:15 p.m.) on
September 25, 2007, in accordance with
the requirements in the ‘‘Submissions’’
section below.
Written Submissions: In lieu of or in
addition to participating in the hearing,
interested parties are invited to submit
written statements or briefs concerning
these investigations. All written
submissions, including requests to
appear at the hearing, statements, and
briefs, should be addressed to the
Secretary, United States International
Trade Commission, 500 E Street, SW.,
Washington, DC 20436. Pre-hearing
briefs and statements should be filed not
later than 5:15 p.m., September 26,
2007; and post-hearing briefs and
statements and all other written
submissions should be filed not later
than 5:15 p.m., October 24, 2007. All
written submissions must conform with
the provisions of section 201.8 of the
Commission’s Rules of Practice and
Procedure (19 CFR 201.8). Section 201.8
of the rules requires that a signed
original (or a copy designated as an
original) and fourteen (14) copies of
each document be filed. In the event
that confidential treatment of the
document is requested, at least four (4)
additional copies must be filed, in
which the confidential information
must be deleted (see the following
paragraph for further information
regarding confidential business
information). The Commission’s rules
do not authorize filing submissions with
the Secretary by facsimile or electronic
means, except to the extent permitted by
section 201.8 of the rules (see Handbook
for Electronic Filing Procedures, https://
www.usitc.gov/secretary/
fed_reg_notices/rules/documents/
handbook_on_electronic_filing.pdf).
Persons with questions regarding
electronic filing should contact the
Secretary (202–205–2000).
Any submissions that contain
confidential business information must
also conform with the requirements of
section 201.6 of the Commission’s Rules
of Practice and Procedure (19 CFR
201.6). Section 201.6 of the rules
requires that the cover of the document
and the individual pages be clearly
marked as to whether they are the
‘‘confidential’’ or ‘‘nonconfidential’’
version, and that the confidential
business information be clearly
identified by means of brackets. All
PO 00000
Frm 00084
Fmt 4703
Sfmt 4703
written submissions, except for
confidential business information, will
be made available in the Office of the
Secretary to the Commission for
inspection by interested parties.
The Commission may include some or
all of the confidential business
information submitted in the course of
these investigations in the report it
sends to the USTR. As requested by the
USTR, the Commission will publish a
public version of the report, which will
exclude portions of the report that the
USTR has classified as confidential as
well as any confidential business
information.
Issued: September 12, 2007.
By order of the Commission.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. E7–18408 Filed 9–18–07; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II and prior
to issuing a registration under 21 U.S.C.
952(a) authorizing the importation of
such substances, provide manufacturers
holding registrations for the bulk
manufacture of the substance an
opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on October
10, 2006, Lannett Company
Incorporated, 9001 Torresdale Avenue,
Philadelphia, Pennsylvania 19136,
made application by letter and
subsequent renewal on February 19,
2007 to the Drug Enforcement
Administration (DEA) for registration as
an importer of the basic classes of
controlled substances:
Drug
Tetrahydrocannabinols (7370) .....
Methylphenidate (1724) ................
Morphine (9300) ...........................
Schedule
I
II
II
The company plans to import the
basic classes of controlled substances
for analytical testing on a formulated
product for submission to U.S. Food and
Drug Administration (FDA) for generic
product approval.
Any manufacturer who is presently,
or is applying to be, registered with DEA
to manufacture such basic classes of
E:\FR\FM\19SEN1.SGM
19SEN1
53606
Federal Register / Vol. 72, No. 181 / Wednesday, September 19, 2007 / Notices
controlled substances may file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), Washington, DC
20537, or any being sent via express
mail should be sent to Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), 2401 JeffersonDavis Highway, Alexandria, Virginia
22301; and must be filed no later than
October 19, 2007.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–43746), all applicants for
registration to import a basic class of
any controlled substances in Schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: September 12, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–18497 Filed 9–18–07; 8:45 am]
BILLING CODE 4410–09–P
Drug
Schedule
Marihuana (7360) .........................
Cocaine (9041) .............................
I
II
The Institute will manufacture small
quantities of cocaine and marihuana
derivatives for use by their customers in
analytical kits, reagents, and reference
standards as directed by NIDA.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than November 19, 2007.
Dated: September 12, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–18446 Filed 9–18–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Occupational Safety and Health
Administration
[Docket No. OSHA–2007–0064]
Federal Advisory Council on
Occupational Safety and Health
(FACOSH): Announcement of Meeting
Occupational Safety and Health
Administration (OSHA), Labor.
ACTION: Announcement of meeting.
AGENCY:
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
rwilkins on PROD1PC63 with NOTICES
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on August 24, 2007,
Research Triangle Institute, Kenneth H.
Davis Jr., Hermann Building, P.O. Box
12194, East Institute Drive, Research
Triangle, North Carolina 27709, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedules I and II:
VerDate Aug<31>2005
16:58 Sep 18, 2007
Jkt 211001
SUMMARY: The Federal Advisory Council
on Occupational Safety and Health
(FACOSH) will meet October 11, 2007,
in Washington, DC.
DATES: FACOSH meeting: FACOSH will
meet from 1 p.m. to 4:30 p.m.,
Thursday, October 11, 2007.
Submission of comments and requests
to speak: Comments and requests to
speak at the FACOSH meeting must be
received by October 4, 2007.
ADDRESSES: FACOSH meeting: FACOSH
will meet in Room C–5521, Conference
Room 4, U.S. Department of Labor, 200
Constitution Avenue, NW., Washington,
DC 20210.
PO 00000
Frm 00085
Fmt 4703
Sfmt 4703
Submission of comments and requests
to speak: Comments and requests to
speak at the FACOSH meeting,
identified by OSHA Docket No. 2007–
0064, may be submitted by any of the
following methods:
Electronically: You may submit
materials, including attachments,
electronically at: https://
www.regulations.gov, the Federal
eRulemaking Portal. Follow the online
instructions for making submissions.
Facsimile: If your submission,
including attachments, is not longer
than 10 pages, you may fax it to the
OSHA Docket Office at (202) 693–1648.
Mail, express delivery, hand delivery,
messenger or courier service: Submit
three copies of your submissions to the
OSHA Docket Office, Room N–2625,
U.S. Department of Labor, 200
Constitution Avenue, NW., Washington,
DC 20210; telephone (202) 693–2350
(OSHA’s TTY number is (877) 889–
5627). Deliveries (hand, express mail,
messenger and courier service) are
accepted during the Department of
Labor’s and OSHA Docket Office’s
normal business hours, 8:15 a.m.–4:45
p.m., e.t.
Instructions: All submissions must
include the Agency name and docket
number for this Federal Register notice
(Docket No. OSHA–2007–0064).
Submissions in response to this Federal
Register notice, including personal
information provided, will be posted
without change at: https://
www.regulations.gov. Therefore, OSHA
cautions interested parties about
submitting personal information such as
social security numbers and birth dates.
Because of security-related procedures,
submissions by regular mail may result
in a significant delay in their receipt.
Please contact the OSHA Docket Office,
at the address above, for information
about security procedures for making
submissions by hand delivery, express
delivery, and messenger or courier
service. For additional information on
submitting comments and requests to
speak, see the SUPPLEMENTARY
INFORMATION section below.
Docket: To read or download
submissions, go to https://
www.regulations.gov. All documents in
the docket are listed in the https://
www.regulations.gov index. Although
listed in the index, some documents
(e.g., copyrighted material) are not
publicly available to read or download
through https://www.regulations.gov. All
submissions, including copyrighted
material, are available for inspection
and copying at the OSHA Docket Office
at the address above.
FOR FURTHER INFORMATION CONTACT: For
general information: Diane Brayden,
E:\FR\FM\19SEN1.SGM
19SEN1
]]>Agencies
[Federal Register Volume 72, Number 181 (Wednesday, September 19, 2007)]
[Notices]
[Pages 53605-53606]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-18497]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in schedule I or II and prior to issuing a
registration under 21 U.S.C. 952(a) authorizing the importation of such
substances, provide manufacturers holding registrations for the bulk
manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with 21 CFR 1301.34(a), this is notice
that on October 10, 2006, Lannett Company Incorporated, 9001 Torresdale
Avenue, Philadelphia, Pennsylvania 19136, made application by letter
and subsequent renewal on February 19, 2007 to the Drug Enforcement
Administration (DEA) for registration as an importer of the basic
classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)............... I
Methylphenidate (1724)..................... II
Morphine (9300)............................ II
------------------------------------------------------------------------
The company plans to import the basic classes of controlled
substances for analytical testing on a formulated product for
submission to U.S. Food and Drug Administration (FDA) for generic
product approval.
Any manufacturer who is presently, or is applying to be, registered
with DEA to manufacture such basic classes of
[[Page 53606]]
controlled substances may file comments or objections to the issuance
of the proposed registration and may, at the same time, file a written
request for a hearing on such application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21 CFR 1316.47.
Any such comments or objections being sent via regular mail should
be addressed, in quintuplicate, to the Drug Enforcement Administration,
Office of Diversion Control, Federal Register Representative (ODL),
Washington, DC 20537, or any being sent via express mail should be sent
to Drug Enforcement Administration, Office of Diversion Control,
Federal Register Representative (ODL), 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be filed no later than October 19,
2007.
This procedure is to be conducted simultaneously with and
independent of the procedures described in 21 CFR 1301.34(b), (c), (d),
(e), and (f). As noted in a previous notice published in the Federal
Register on September 23, 1975, (40 FR 43745-43746), all applicants for
registration to import a basic class of any controlled substances in
Schedule I or II are and will continue to be required to demonstrate to
the Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration, that the requirements for such registration
pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b),
(c), (d), (e), and (f) are satisfied.
Dated: September 12, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-18497 Filed 9-18-07; 8:45 am]
BILLING CODE 4410-09-P
